Speece Thorson Capital Group Inc. Has $15.77 Million Position in DaVita Inc. (NYSE:DVA)

Speece Thorson Capital Group Inc. trimmed its holdings in DaVita Inc. (NYSE:DVA) by 0.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 105,418 shares of the company’s stock after selling 641 shares during the quarter. DaVita comprises about 3.1% of Speece Thorson Capital Group Inc.’s portfolio, making the stock its 11th biggest position. Speece Thorson Capital Group Inc.’s holdings in DaVita were worth $15,765,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Epoch Investment Partners Inc. acquired a new position in DaVita in the fourth quarter valued at approximately $55,100,000. Invesco Ltd. increased its stake in shares of DaVita by 20.9% in the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company’s stock valued at $237,716,000 after acquiring an additional 275,284 shares in the last quarter. Amundi lifted its position in shares of DaVita by 116.4% during the 4th quarter. Amundi now owns 446,386 shares of the company’s stock valued at $68,726,000 after acquiring an additional 240,126 shares during the period. Bridgewater Associates LP boosted its stake in DaVita by 298.4% during the fourth quarter. Bridgewater Associates LP now owns 239,970 shares of the company’s stock worth $35,888,000 after acquiring an additional 179,744 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ grew its holdings in DaVita by 256.8% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company’s stock worth $24,301,000 after purchasing an additional 116,758 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Price Performance

DaVita stock opened at $140.21 on Friday. DaVita Inc. has a 52 week low of $128.69 and a 52 week high of $179.60. The company’s 50 day moving average price is $149.13 and its two-hundred day moving average price is $156.00. The stock has a market cap of $11.22 billion, a P/E ratio of 13.05, a P/E/G ratio of 1.07 and a beta of 1.04. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, equities analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on DVA. Barclays raised their target price on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 18th. Cowen reissued a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. StockNews.com upgraded shares of DaVita from a “hold” rating to a “buy” rating in a report on Thursday, April 10th. Finally, Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, DaVita has a consensus rating of “Hold” and an average target price of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.